{"id":"W4237480749","doi":"10.2165/00128413-200514870-00042","title":"Health Canada has approved pegaptanib","year":2005,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Cardiac, Anesthesia and Surgical Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pegaptanib; Pharmacy; Family medicine; Internal medicine; Bevacizumab; Ranibizumab","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008004645,0.0003087181,0.0004868275,0.0006941024,0.001341886,0.001370871,0.0007151391,0.002431104,0.01887437],"category_scores_gemma":[0.00266278,0.000212391,0.0006685522,0.00057615,0.0007468538,0.0003141653,0.0004515706,0.002524073,0.004239227],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.007376669,"about_ca_system_score_gemma":0.01865073,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.1421767,"about_ca_topic_score_gemma":0.3004983,"domain_scores_codex":[0.9990712,0.0001362719,0.00005360836,0.00007604592,0.000409382,0.000253489],"domain_scores_gemma":[0.9978631,0.0004164975,0.0001875699,0.00007525371,0.0006876238,0.0007699354],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003830986,0.001231057,0.0246901,0.000463787,0.0002123866,0.002833052,0.0001320459,0.0005016675,0.009507255,0.006261316,0.4901907,0.4601457],"study_design_scores_gemma":[0.002160476,0.001303035,0.02598919,0.0002102551,0.0001680173,0.00254165,0.0001172867,0.0009269232,0.00709336,0.0008550609,0.9585893,0.00004548378],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"editorial","genre_scores_codex":[0.1305516,0.0326067,0.004680216,0.2371183,0.01256173,0.001399623,0.005926332,0.002270455,0.572885],"genre_scores_gemma":[0.532718,0.01269037,0.00781431,0.08230088,0.002854767,0.000316335,0.005421193,0.0002596392,0.3556245],"genre_candidate":"editorial","genre_consensus":null,"teacher_disagreement_score":0.8578233,"threshold_uncertainty_score":0.2826983,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02521359520860511,"score_gpt":0.2775660869015151,"score_spread":0.25235249169291,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}